<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"
  dtd-version="1.3" xml:lang="en" article-type="research-article">
  <?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
  <?DTDIdentifier.IdentifierType public?>
  <?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
  <?SourceDTD.Version 1.2?>
  <?ConverterInfo.XSLTName jats2jats3.xsl?>
  <?ConverterInfo.Version 1?>
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="iso-abbrev">Arch Pharm Pract</journal-id>
      <journal-id journal-id-type="publisher-id">archivepp.com</journal-id>
      <journal-id journal-id-type="publisher-id">Arch Pharm Pract</journal-id>
      <journal-title-group>
        <journal-title>Archives of Pharmacy Practice</journal-title>
      </journal-title-group>
      <issn pub-type="epub">2320-5210</issn>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id">archivepp.com-1022</article-id>
      <article-id pub-id-type="doi">10.51847/lXDZ0BFUJ7</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original research</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Warfarin Therapy Improved Migraine Headaches with Aura: A Case Report</article-title>
      </title-group>
                  <pub-date pub-type="epub">
        <day>16</day>
        <month>03</month>
        <year>2023</year>
      </pub-date>
      <volume>14</volume>
      <issue>1</issue>
      <fpage>66</fpage>
      <lpage>68</lpage>
      <permissions>
        <copyright-statement>
          Copyright: &#x000a9; 2026 Archives of Pharmacy Practice
        </copyright-statement>
        <copyright-year>2026</copyright-year>
        <license>
          <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/"
            specific-use="textmining" content-type="ccbyncsalicense">
            https://creativecommons.org/licenses/by-nc-sa/4.0/</ali:license_ref>
          <license-p>This is an open access journal, and articles are distributed under the terms of
            the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows
            others to remix, tweak, and build upon the work non-commercially, as long as appropriate
            credit is given and the new creations are licensed under the identical terms.</license-p>
        </license>
      </permissions>
      <abstract>
        <title>A<sc>BSTRACT</sc></title>
        <p>Warfarin therapy is indicated for patients generally requiring anticoagulation therapy. Warfarin&amp;#39;s common indications include myocardial infarction (MI), deep vein thrombosis (DVT), and stroke. Warfarin is favorable for many clinicians because it allows for direct monitoring. Furthermore, it comes in many doses which offer options for providers to ensure optimal anticoagulation for patients through monitoring of the International Normalized Ratio (INR). Warfarin acts as a vitamin K antagonist, preventing the synthesis of certain coagulation factors. Another benefit of warfarin is that it can be reversed using vitamin K. Literature reports have demonstrated warfarin&amp;#39;s benefit in some adult patients for migraine headaches. Although these findings are scarce and incidental, we report a case of a 52-year-old male for whom warfarin was instrumental in maintaining the abortive benefit of migraine headaches and associated visual disturbances. The case report illustrates the possible added benefit of continuing warfarin therapy for patients with migraine headaches regardless of the primary indication for the warfarin therapy. </p>
      </abstract>
      <kwd-group>
              </kwd-group>
    </article-meta>
  </front>
</article>